Kala Bio confirms terms of exclusive Virotek eye genetic testing distribution deal
A newly filed exhibit lays out how Kala's exclusivity, profit split, and termination rights work under its September 3, 2026 agreement with Virotek.
SEC filing
Latest
2 stories
Thursday, September 10
Wednesday, July 22
KALA BIO files for up to $250 million at-the-market stock offering
The company, pivoting from failed eye disease trials to an AI platform business, filed a prospectus supplement to sell shares through H.C. Wainwright & Co.
SEC filing